On May 17, the FDA approved the first preventive injection for migraine, erenumab-aooe (Aimovig, Amgen).
Erenumab-aooe, a once-monthly self-injection, works by blocking calcitonin gene–related peptides, a molecule involved in migraine. The drug is supported by three previous clinical trials, all comparing patient use of the medication with placebo. In the first trial of 955 patients, after six months the treatment group saw on average one or two fewer migraine episodes a month. The other